Unicycive Therapeutics Inc (UNCY) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Unicycive Therapeutics Inc stock (UNCY) is currently trading at $6.65. Unicycive Therapeutics Inc PS ratio (Price-to-Sales) is 23.75. Analyst consensus price target for UNCY is $46.50. WallStSmart rates UNCY as Sell.
- UNCY PE ratio analysis and historical PE chart
- UNCY PS ratio (Price-to-Sales) history and trend
- UNCY intrinsic value — DCF, Graham Number, EPV models
- UNCY stock price prediction 2025 2026 2027 2028 2029 2030
- UNCY fair value vs current price
- UNCY insider transactions and insider buying
- Is UNCY undervalued or overvalued?
- Unicycive Therapeutics Inc financial analysis — revenue, earnings, cash flow
- UNCY Piotroski F-Score and Altman Z-Score
- UNCY analyst price target and Smart Rating
Unicycive Therapeutics Inc
📊 No data available
Try selecting a different time range
Smart Analysis
Unicycive Therapeutics Inc (UNCY) · 5 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Concerns around market cap and return on equity. Significant fundamental concerns warrant caution or avoidance.
Unicycive Therapeutics Inc (UNCY) Key Strengths (0)
Supporting Valuation Data
Unicycive Therapeutics Inc (UNCY) Areas to Watch (5)
Company is destroying shareholder value
Very expensive at 23.8x annual revenue
Micro-cap company with very limited liquidity and high volatility
Premium pricing at 3.9x book value
Moderate institutional interest at 39.74%
Supporting Valuation Data
Unicycive Therapeutics Inc (UNCY) Detailed Analysis Report
Overall Assessment
This company scores 14/100 in our Smart Analysis, earning a F grade. Out of 5 metrics analyzed, 0 register as strengths (avg 0/10) while 5 fall into concern territory (avg 3.0/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
Limited fundamental strengths were identified. The bull case requires improvement in core metrics.
The Bear Case
The primary concerns are Return on Equity, Price/Sales, Market Cap. Some valuation metrics including Price/Sales (23.75), Price/Book (3.86) suggest expensive pricing. Profitability pressure is visible in Return on Equity at -102.30%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -102.30% needing improvement to support the investment thesis. Third, top-line growth trajectory.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Price/Sales are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
UNCY Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
UNCY's Price-to-Sales ratio of 23.75x trades at a deep discount to its historical average of 53.95x (40th percentile). The current valuation is 89% below its historical high of 217.78x set in Feb 2026, and 121% above its historical low of 10.76x in Aug 2024. Over the past 12 months, the PS ratio has expanded from ~19.5x, reflecting growing market expectations outpacing revenue growth.
WallStSmart Analysis Synopsis
Data-driven financial summary for Unicycive Therapeutics Inc (UNCY) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
Unicycive Therapeutics Inc operates as a stable business with moderate growth and solid fundamentals.
Key Findings
Debt-to-equity ratio of 0.01 indicates a conservative balance sheet with 43M in cash.
Free cash flow is -6M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Volatility is elevated with a beta of 1.82, so expect amplified moves relative to the broader market.
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact Unicycive Therapeutics Inc.
Bottom Line
Unicycive Therapeutics Inc offers stability with moderate growth and solid fundamentals. The valuation may present an opportunity for patient investors, though limited growth means returns will likely come from dividends and modest capital appreciation rather than explosive gains.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Data sourced from SEC Form 4 filings
Last updated: 2:52:25 PM
About Unicycive Therapeutics Inc(UNCY)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
Unicycive Therapeutics Inc. is a clinical-stage biopharmaceutical company committed to transforming the landscape of kidney disease treatment, particularly in addressing hyperphosphatemia and its associated disorders. With its innovative pipeline aimed at regulating phosphorus levels through unique therapeutic mechanisms, Unicycive seeks to improve patient outcomes significantly. The company's strong focus on research and development, coupled with strategic collaborations, positions it well to lead advancements in nephrology care. As Unicycive progresses through its clinical trials, it presents a compelling investment opportunity for institutional investors looking to capitalize on growth in the evolving healthcare sector.